MACURE PHARMA ApS

The company's purpose is to trade in the pharmaceutical industry.

Development in activities and finances

The income statement of the company for 2025 shows a profit of DKK 11,053,564 and at 31 December 2025 the balance sheet of the Company shows equity of DKK 18,033,209.

Management expects to be able to realize a profit for 2026 sligthly above expectations for the financial year.

Profit/loss for the year in relation to expected developments

Management considers that the realized profit for 2025 is in line with the stated outlook for the year in last year management commentary.

No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.

The Entity participates in a Danish joint taxation arrangement where Nest Egg ApSserves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore liable for income taxes etc for the jointly taxed entities, and for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed entities. The jointly taxed entities' total known net liability under the joint taxation arrangement is disclosed in the administration company's financial statements.